Aims To investigate the effect of FTY720 on the valproic acid (VPA) rat model of autism. Main
methods As an animal model of autism, we used intraperitoneal injection of VPA on …

Neuropsychiatric (NP) involvement in systemic lupus erythematosus (SLE) severely impacts
patients' quality of life and leads to a poor prognosis. The current therapeutic protocol …

FTY720 (fingolimod) is an oral sphingosine 1-phosphate (S1P) receptor modulator under
development for the treatment of multiple sclerosis (MS). To elucidate its effects in the central …

Depression is a common aspect of the modern lifestyle, and most patients are recalcitrant to
the current antidepressants. Fingolimod (FTY720), a sphingosine analogue approved for the …

Fingolimod (FTY720) is a sphingosine 1-phosphate (S1P) receptor agonist. Here, to
understand biological activity of FTY720 pretreatment and post-treatment on cerebral …

Accumulating evidence has shown that neuroinflammation plays a key role in
epileptogenesis. However, the efficacy of anti-inflammatory agents for preventing epilepsy …

Huntington's disease (HD) is a hereditary neurodegenerative disorder characterized by
motor and cognitive impairments, involving striatum, cortex and hippocampus. Synaptic and …

Fingolimod (FTY720) is a known sphingosine-1-phosphate (S1P) receptor agonist. Several
studies have shown the therapeutic efficacy of FTY720 in neurodegenerative disorders …

Alzheimer's disease (AD) as a neurodegenerative brain disorder is the most common cause
of dementia. To date, there is no causative treatment for AD and there are few preventive …

Abstract Background FTY720 (fingolimod, Gilenya™), a structural analog of sphingosine-1-
phosphate (S1P), is the first oral drug approved for treatment the relapsing-remitting form of …